Compare CADL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | GEVO |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 468.8M |
| IPO Year | 2021 | 2010 |
| Metric | CADL | GEVO |
|---|---|---|
| Price | $6.26 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $19.00 | $6.58 |
| AVG Volume (30 Days) | 1.7M | ★ 5.0M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.62 | ★ 58.82 |
| EPS | N/A | ★ N/A |
| Revenue | $125,000.00 | ★ $711,000.00 |
| Revenue This Year | N/A | $19.44 |
| Revenue Next Year | N/A | $5.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.34 | $1.00 |
| 52 Week High | $7.66 | $2.97 |
| Indicator | CADL | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 37.89 |
| Support Level | $5.42 | $1.72 |
| Resistance Level | $6.41 | $1.89 |
| Average True Range (ATR) | 0.48 | 0.11 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 51.30 | 37.23 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.